Phase 3 ECHELON-2 clinical trial evaluating ADCETRIS plus CHP meets primary endpoint

Seattle Genetics, Inc. and Takeda Pharmaceutical Company Limited announced today that the phase 3 ECHELON-2 clinical trial met its primary endpoint.

Source link

Related posts

CDC IDs Outbreak Trends Tied to Treated Recreational Water


Antidepressants Improve Disease Course in IBD


A murine model demonstrating reversal of structural and functional correlates of cirrhosis with progenitor cell transplantation


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy